Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors

Future Medicinal Chemistry

Volumn 3, Issue 9, 2011, Pages 1181-1197

  Ghosh, Arun K ^a   Anderson, David D ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; BRECANAVIR; DARUNAVIR; ETHER DERIVATIVE; GRL 0355; GRL 0476; GRL 0519A; GRL 06579A; GRL 98065; INDINAVIR; JE 2147; KNI 764; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SM 309515; TETRAHYDROFURAN DERIVATIVE; TETRAHYDROPYRAN DERIVATIVE; TIPRANAVIR; TMC 126; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

FURANS; HETEROCYCLIC COMPOUNDS; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PYRANS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 79961047353     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.68     Document Type: Review

References (75)

1. Ghosh A, Anderson D, Mitsuya H. The FDA approved HIV-1 protease inhibitors for treatment of HIV/AIDS. In:Burger's Medicinal Chemistry, Drug Discovery and Development (Volume 7). Abraham DJ, Rotella DP (Eds).John Wiley & Sons, Inc., Hoboken, NJ, USA 1-74 (2010).
2. Roberts N, Martin J, Kinchington D et al. Rational design of peptide-based HIV proteinase inhibitors. Science 248, 358-361 (1990).
3. Kempf D, Sham H, Marsh K et al. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J. Med. Chem. 41, 602-617 (1998). (Pubitemid 28093094)
4. Dorsey B, Levin R, McDaniel S et al. L-735,524: the design of a potent and orally bioaviable HIV protease inhibitor. J. Med. Chem. 37, 3443-3451 (1994). (Pubitemid 24334599)
5. Kaldor S, Kalish V, Davies J et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40, 3979-3985 (1997). (Pubitemid 27512316)
6. Tung R, Livingston B, Rao B et al. Design and synthesis of amprenavir, a novel HIV protease inhibitor. In: Protease inhibitors in AIDS therapy. Ogden RC, Flexner CW (Ed.), Marcel Dekker, Inc., New York, NY, 101-118 (2001).
7. Falcoz C, Jenkins J, Bye C et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J. Clin. Pharmacol. 42, 887-898 (2002). (Pubitemid 34803852)
8. Bold G, Fassler A, Capraro H et al. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 41, 3387-3401 (1998). (Pubitemid 28406546)
9. Sham H, Kempf D, Molla A. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents. Chemother. 42, 3218-3224 (1998). (Pubitemid 28553744)
10. Turner S, Strohbach J, Tommasi R et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2- pyrone sulfonamide class. J. Med. Chem. 41, 3467-3476 (1998). (Pubitemid 28406555)
11. Koh Y, Ghosh A, Mitsuya H et al. Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47, 3123-3129 (2003). (Pubitemid 37229567)
12. Ghosh A, Krishnan K, Walters D et al. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. Bioorg. Med. Chem. Lett. 8, 687-690 (1998).
13. Ghosh A, Chapsal B. Aspartic acid proteases as therapeutic targets: second-generation approved HIV protease inhibitors for the treatment of HIV/AIDS. In:Methods and Principles in Medicinal Chemistry (Volume 45). Ghosh AK (Ed.).Wiley-VCH, Weinheim, Germany 169-195 (2010).
14. Ghosh A, Chapsal B, Weber I, Mitsuya H. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc. Chem. Res. 41, 78-86 (2008).
15. Ghosh A, Chapsal B. Aspartic acid proteases as therapeutic targets: darunavir, a new PI with dual mechanism: from a novel drug design concept to new hope against drug-resistant HIV. In:Methods and Principles in Medicinal Chemistry (Volume 45). Ghosh AK (Ed.).Wiley-VCH, Weinheim, Germany 205-235 (2010).
16. Ghosh A, Sridhar P, Kumaragurubaran N et al. Bis-tetrahydrofuran: a privileged ligand for Darunavir and a new generation of HIV protease inhibitors that combat drug resistance. ChemMedChem 1, 939-950 (2006). (Pubitemid 44448791)
17. Ghosh A, Thompson J, McKee S et al. Potent HIV protease inhibitors: the development of 3-tetrahydrofuranglycine as P2-ligands and substituted pyrazine derivatives as P3- ligands. J. Med. Chem. 36, 2300-2310 (1993). (Pubitemid 23262461)
18. Ghosh A, Sridhar P, Leshchenko S et al. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J. Med. Chem. 49, 5252-5261 (2006). (Pubitemid 44260221)
19. Ghosh A, Martyr C, Mitsuya H et al. Design of substituted bis-tetrahydrofuran (bis- THF)-derived potent HIV-1 protease inhibitors, protein-ligand X-ray structure, and convenient syntheses of bis-THF and substituted bis-THF ligands. Med. Chem. Lett. 2(4), 298-302 (2011).
20. Ghosh A, Xu C, Rao, K et al. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors. ChemMedChem. 5, 1850-1854 (2010).
21. Koh Y, Ghosh A, Mitsuya H et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 282, 28709-28720 (2007). (Pubitemid 47606016)
22. Ghosh A, Chapsal B, Baldridge A et al. Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors. Org. Lett. 10, 5135-5138 (2008).
23. Ghosh A, Gemma S, Takayama J et al. Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand x-ray studies. Org. Biomol. Chem. 6, 3703-3713 (2008).
24. Ghosh A, Gemma S, Baldridge A et al. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand x-ray studies. J. Med. Chem. 51, 6021-6033 (2008).
25. Ghosh A, Chapsal B, Mitsuya H et al. Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P2 ligands: structure-activity studies and biological evaluation. J. Med. Chem. 54(2).622-634 (2011).
26. Ahn J, Boyle N, MacDonald M, Janda K. Peptidomimetics and peptide backbone modifications. Mini-Rev. Med. Chem. 2, 463-473 (2002).
27. Ciapetti P, Giethlen B. Molecular variations based on isosteric replacements. In:The Practice of Medicinal Chemistry (Third Edition). Wermuth CG (Ed.).Academic Press, St Louis, MO, USA 290-342 (2008).
28. Whiting M, Tripp J, Fokin V et al. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization. J Med Chem. 49, 7697-7710 (2006). (Pubitemid 46033661)
29. Giffin M, Heaslet H, Torbett B et al. A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. J. Med. Chem. 51, 6263-6270 (2008).
30. Brik A, Wlodawer A, Goodsell D et al. 1,2,-triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors. ChemBioChem 6, 1167-1169 (2005). (Pubitemid 40978173)
31. Whiting M, Elder J, Fokin V et al. Inhibitors of HIV-1 protease by using in situ click chemistry. Angew. Chem. Int. Ed. 45, 1435-1439 (2006). (Pubitemid 44097627)
32. Jochim A, Miller S, Angelo N, Arora P. Evaluation of triazolamers as active site inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett. 19, 6023-6026 (2009).
33. Kim R, Rouse E, Chapman K et al. P1′oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1. Bioorg. Med. Chem. Lett. 14, 4651-4654 (2004). (Pubitemid 39490283)
34. Lu Z, Bohn J, Rano T et al. Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus. Bioorg. Med. Chem. Lett. 15, 5311-5314 (2005). (Pubitemid 41463671)
35. Miller J, Andrews C, Sherrill R et al. Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorg. Med. Chem. Lett. 16, 1788-1794 (2006). (Pubitemid 43267351)
36. Yeung C, Klein L, Flentge C et al. Oximinoarylsulfonamides as potent HIV protease inhibitors. Bioorg. Med. Chem. Lett. 15, 2275-2278 (2005). (Pubitemid 40523085)
37. GlaxoSmithKline. GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir. Press release, 18 December (2006).
38. Bonini C, Chiummiento L, De Bonis M et al. Synthesis, biological activity and modeling studies of two novel anti HIV PR inhibitors with a thiophene containing hydroxyethylamino core. Tetrahedron 61, 6580-6589 (2005). (Pubitemid 40812960)
39. Bonini C, Chiummiento L, De Bonis M et al. Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases. J. Med. Chem. 53, 1451-1457 (2010).
40. Chang M, Giffin M, Savage J et al. Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem. J. 429, 572-532 (2010).
41. Specker E, Bottcher J, Klebe G et al. An old target revisited: two new privileged skeletons and an unexpected binding mode for HIV-protease inhibitors. Angew. Chem. Int. Ed. 44, 3140-3144 (2005). (Pubitemid 40689862)
42. Specker E, Bottcher J, Klebe G et al. Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease. ChemMedChem 1, 106-117 (2006). (Pubitemid 44104983)
43. Bottcher J, Blum A, Klebe G et al. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors. ChemMedChem 3, 1337-1344 (2008).
44. Blum A, Bottcher J, Diederich W et al. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold. J. Med. Chem. 51, 2078-2087 (2008). (Pubitemid 351503263)
45. Bottcher J, Blum A, Heine A, Diederich W, Klebe G. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease. J. Mol. Biol. 383, 347-357 (2008).
46. Brass S, Chan N, Diederich W et al. Synthesis of 2,3,4,6-tetrahydro-1H- azepines as privileged ligand scaffolds for the design of aspartic protease inhibitors via a ring-closing metathesis approach. J. Orgmet. Chem. 691, 5406-5422 (2006). (Pubitemid 44791378)
47. Mimoto T, Terashima K, Nojima S et al. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure. Biorg. Med. Chem. 12, 281-293 (2004). (Pubitemid 38096241)
48. Mimoto T, Nojima S, Terashima K et al. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2- chlorobenzoyl-allophenylnorstatine structure. Bioorg. Med. Chem. Lett. 16 1299-1308 (2008). (Pubitemid 351191770)
49. Raghavan S, Lu Z, Beeson T et al. Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus. Bioorg. Med. Chem. Lett. 17, 5432-5436 (2007). (Pubitemid 47391269)
50. Ghosh A, Gemma S, Simoni E et al. Synthesis and biological evaluation of novel allophenynorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands. Bioorg. Med. Chem. Lett. 20, 1241-1246 (2010).
51. Abdel-Rahman H, El-Koussi N, Alkaramany G et al. Allophenylnorstatine- containing HIV-1 protease inhibitors: desing, synthesis and structure-activity relationships for selected P2 ligands. Bull. Pharm. Sci. 28, 95-103 (2005).
52. Ami E, Nakahara K, Kiso Y et al. Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating d-cysteine derivatives as P2/P3 moieties. Bioorg. Med. Chem. Lett. 17, 4213-4217 (2007). (Pubitemid 47021398)
53. Hidaka K, Kimura T, Kiso Y et al. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2′ pocket. J. Med. Chem. 52, 7604-7617 (2009).
54. Ali A, Reddy G, Rana T et al. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone- 5-carboxamides as novel P2 ligands. J. Med. Chem. 49, 7342-7356 (2006). (Pubitemid 44913395)
55. Reddy G, Ali A, Rana T et al. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2′ ligands in pseudosymmetric dipeptide isosteres. J. Med. Chem. 50, 4316-4328 (2007). (Pubitemid 47378831)
56. Ali A, Schiffer C, Rana T et al. Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. J. Med. Chem. 53, 7699-7708 (2010).
57. Smith A, Charnley A, Harada H et al. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2′ side chains. Bioorg. Med. Chem. Lett. 16, 859-863 (2006). (Pubitemid 43059838)
58. Sherrill R, Andrews C, Bock W. Optimization of pyrrolidinone based HIV protease inhibitors. Bioorg. Med. Chem. Lett. 15, 81-84 (2005). (Pubitemid 39575787)
59. Koh Y, Das D, Mitsuya H et al. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a Stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 52, 3902-3914 (2009).
60. Ghosh A, Leshchenko-Yashchuk S, Anderson D et al. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1′-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein- ligand x-ray studies. J. Med. Chem. 52, 3902-3914 (2009).
61. Flosi W, DeGoey D, Grampovnik D et al. Discovery of imidazolidine-2,4- dione-linked HIV protease inhibitors with activity against lopinavir-reistant mutant HIV. Bioorg. Med. Chem. 14, 6695-6712 (2006). (Pubitemid 44233307)
62. Randolph J, Huang P, Flosi W et al. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors. Bioorg. Med. Chem. 14, 4035-4046 (2006).
63. Kazmierksi W, Furfine E, Spaltenstein A, Wright L. New, potent P1/P2-morpholinone-based HIV-protease inhibitors. Bioorg. Med. Chem. Lett. 16, 5226-5230 (2006). (Pubitemid 44262495)
64. Chrusciel R, Nicholas J, Thaisrivongs S. HIV protease inhibitors in early development. In:Protease Inhibitors in AIDS Therapy . Ogden RC, Flexner CW (Eds).Marcel Dekker, Inc., NY, USA 119-138 (2001).
65. Zhao C, Sham H, Sun M et al. Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains. Bioorg. Med. Chem. Lett. 15, 5499-5503 (2005). (Pubitemid 41562978)
66. Zaman S, Campaner P, Abell A. Synthesis of amino acid derived seven-membered lactams by RCM and their evaluation against HIV protease. Bioorg. Med. Chem. Lett. 14, 8323-8331 (2006). (Pubitemid 44667549)
67. Ax A, Schaal W, Vrang L, Samuelsson B, Hallberg A, Karlen A. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2′ to P1/P1′. Bioorg. Med. Chem. 13, 755-764 (2005). (Pubitemid 40093618)
68. Sham H, Zhao C, Marsh K et al. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease. Biochem. Biophys. Res. Commun. 225, 436-440 (1996). (Pubitemid 26355619)
69. Sham H, Zhao C, Stewart K et al. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. J. Med. Chem. 39, 392-397 (1996). (Pubitemid 26041452)
70. Gold H, Ax A, Larhed M et al. Fast and selective synthesis of novel cyclic sulfamide HIV-1 protease inhibitors under controlled microwave heating. Tetrahedron 62, 4671-4675 (2006).
71. Ax A, Joshi A, Larhed M et al. Synthesis of a small library of non-symmetric cyclic sulfamide HIV-1 protease inhibitors. Tetrahedron 66, 4049-4056 (2010).
72. Amano M, Koh Y, Mitsuya H et al. A novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 51, 2143-2155 (2007). (Pubitemid 46903107)
73. Wang Y, Tie Y, Weber I et al. Potent new antiviral compounds shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. J. Med. Chem. 50, 4509-4515 (2007). (Pubitemid 47378847)
74. Ghosh A, Schiltz G, Perali R et al. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2-ligands. Bioorg. Med. Chem. Lett. 16, 1869-1873 (2006). (Pubitemid 43267367)
75. He M, Zhang H, Yang M et al. Design, biological evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors. Chem Biol. Drug Des. 76, 174-180 (2010).